{"id":140689,"title":"Archived 39: Summary of NACI statement of September 1, 2022: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T14:13:56.390000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-bivalent-omicron-containing-mrna-covid-19-vaccines/summary-september-1-2022.html?wbdisable=true","snippet":"Archived 39: Summary of NACI statement of September 1, 2022: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines - Canada.ca Skip to main content Skip to \"About government\" We have archived this page and will not be updating it. You can use it for…","rawSnapshotUrl":"/api/snapshots/raw/140689","browseUrl":"https://replay.healtharchive.ca/job-1/20250418141356/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-bivalent-omicron-containing-mrna-covid-19-vaccines/summary-september-1-2022.html?wbdisable=true#ha_snapshot=140689","mimeType":"text/html","statusCode":200}